eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, is an activator of anti-tumor immune response

被引：0

作者：

Webster, Kevin ^{[1
]}

Sharma, Rajesh ^{[1
]}

Goel, Vikas ^{[1
]}

Stumpf, Craig ^{[1
]}

Stauton, Jocelyn ^{[1
]}

Thompson, Peggy ^{[1
]}

Chiang, Gary ^{[1
]}

Xu, Yichen ^{[2
]}

Jin, Hyun Yong ^{[2
]}

Ruggero, Davide ^{[2
]}

机构：

[1] eFFECTOR Therapeut, San Diego, CA USA

[2] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P368

引用

页数：2

共 50 条

[31] Highly potent and selective DNA-PK inhibitor M3814 with sustainable anti-tumor activity in combination with radiotherapy
Fuchss, Thomas
Mederski, Werner W.
Emde, Ulrich
Buchstallter, Hans-Peter
Zenke, Frank
Zimmermann, Astrid
Sirrenberg, Christian
Vassilev, Lubo
Damstrup, Lars
Urbahns, Klaus
Blaukat, Andree
CANCER RESEARCH, 2017, 77
[32] Exploratory Research for HIF-1α Overexpression Tumor Antigen in the Activation of Dendritic Cells and the Potent Anti-Tumor Immune Response
Zhao, Jinjin
Zhang, Haiguang
Zhao, Yilin
Lin, Zhiqiang
Lin, Fei
Wang, Zhiyin
Mo, Qingjiang
Lu, Guangjian
Zhao, Guoan
Wang, Guoqiang
CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 1813 - 1822
[33] ETS-005, a highly selective TEAD4 palmitoylation inhibitor with potent anti-tumor activity and brain penetrating capability
Lu, Jiajun
Du, Wenpei
Gao, Ming
Fan, Xiaofei
Li, Jinping
Feng, Lijian
Wang, Mengya
Li, Yingjie
Zhong, Xiaofeng
Cui, Wenqi
Zheng, Qiangang
Zhu, Jidong
CANCER RESEARCH, 2024, 84 (06)
[34] BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity
Scholz, Arne
Luecking, Ulrich
Siemeister, Gerhard
Lienau, Philip
Eis, Knut
Wengner, Antje
Petersen, Kirstin
Boemer, Ulf
Nussbaumer, Peter
Choidas, Axel
Ruehter, Gerd
Eickhoff, Jan
Schultz-Fademrecht, Carsten
Klebl, Bert
Ince, Stuart
von Nussbaum, Franz
Mumberg, Dominik
Brands, Michael
Ziegelbauer, Karl
CANCER RESEARCH, 2014, 74 (19)
[35] Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model
Ghaedi, Mojgan
Golsaz-Shirazi, Forough
Bahadori, Tannaz
Khoshnoodi, Jalal
Mortezagholi, Sahar
Jeddi-Tehrani, Mahmood
Amiri, Mohammad Mehdi
Shokri, Fazel
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (06) : 2437 - 2450
[36] Potent anti-tumor immune response and tumor growth inhibition induced by HER2 subdomain fusion protein in a mouse tumor model
Mojgan Ghaedi
Forough Golsaz-Shirazi
Tannaz Bahadori
Jalal Khoshnoodi
Sahar Mortezagholi
Mahmood Jeddi-Tehrani
Mohammad Mehdi Amiri
Fazel Shokri
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 2437 - 2450
[37] Highly potent and selective RET inhibitor with robust anti-tumor activities against wild-type and acquired drug-resistant mutations
Xing, Li
Zhu, Wei
Wang, Jingbing
CANCER RESEARCH, 2024, 84 (07)
[38] Highly potent and selective ATM kinase inhibitor M4076: A clinical candidate drug with strong anti-tumor activity in combination therapies
Fuchss, Thomas
Graedler, Ulrich
Schiemann, Kai
Kuhn, Daniel
Kubas, Holger
Dahmen, Heike
Zimmermann, Astrid
Zenke, Frank
Blaukat, Andree
CANCER RESEARCH, 2019, 79 (13)
[39] A highly selective Erk1/2 Inhibitor with in-vivo anti tumor potency
Seipelt, Irene
Guenther, Eckhard
Blumenstein, Lars
Mueller, Gilbert
Schmidt, Peter
Aicher, Babette
Teifel, Michael
Gerlach, Matthias
CANCER RESEARCH, 2011, 71
[40] Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity
Abdelaziz, Ahmed M.
Diab, Sarah
Islam, Saiful
Basnet, Sunita K. C.
Noll, Benjamin
Li, Peng
Mekonnen, Laychiluh B.
Lu, Jingfen
Albrecht, Hugo
Milne, Robert W.
Gerber, Cobus
Yu, Mingfeng
Wang, Shudong
MEDICINAL CHEMISTRY, 2019, 15 (06) : 602 - 623

← 1 2 3 4 5 →